ACHV vs. LXRX, VSTM, RIGL, EBS, XOMA, VNDA, IRWD, CDXS, CBIO, and SGMO
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), Crescent Biopharma (CBIO), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences vs. Its Competitors
Achieve Life Sciences (NASDAQ:ACHV) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 3.0% of Achieve Life Sciences shares are held by insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Achieve Life Sciences has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -206.43%. Lexicon Pharmaceuticals' return on equity of -83.63% beat Achieve Life Sciences' return on equity.
Achieve Life Sciences has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Achieve Life Sciences has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.
In the previous week, Lexicon Pharmaceuticals had 6 more articles in the media than Achieve Life Sciences. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 1 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.50 beat Lexicon Pharmaceuticals' score of 0.47 indicating that Achieve Life Sciences is being referred to more favorably in the media.
Achieve Life Sciences presently has a consensus target price of $12.00, indicating a potential upside of 289.61%. Lexicon Pharmaceuticals has a consensus target price of $3.23, indicating a potential upside of 119.39%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Achieve Life Sciences is more favorable than Lexicon Pharmaceuticals.
Summary
Achieve Life Sciences and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ACHV) was last updated on 10/16/2025 by MarketBeat.com Staff
